Overview
News
Technologies
Salaries
Products
People
Growth
Financials

Overview

Superluminal Medicines is a software led drug discovery company focused on helping researchers find and develop new medicines more efficiently. From its positioning and messaging, the core problem it tackles is the time and cost involved in identifying promising drug candidates and understanding how they might behave, a process that is often slowed down by fragmented data, complex biology, and long experimental cycles. Superluminal appears to address this by building computational tools that support decision making earlier in the discovery pipeline, aiming to help teams prioritise the most viable options before committing heavily to lab work.

News

Blog 1 year ago
"Biopharma returns to MC4R for drugs targeting genetic obesity as well as appetite loss." Featured Story on Endpoints News by Kyle LaHucik
The post "Biopharma returns to MC4R for drugs targeting genetic obesity as well as appetite loss." Featured Story on Endpoints News by Kyle LaHucik appeared first on Superluminal.
Read more
Report
Blog 1 year ago
Optimizing Drug Design by Merging Generative AI With Active Learning Frameworks: Published in Communications Chemistry
The post Optimizing Drug Design by Merging Generative AI With Active Learning Frameworks: Published in Communications Chemistry appeared first on Superluminal.
Read more
Report
News Nature 1 year ago
Optimizing drug design by merging generative AI with a physics-based active learning framework
Machine learning is transforming drug discovery, with generative models (GMs) gaining attention for their ability to design molecules with specific properties. However, GMs often struggle with target engagement, synthetic accessibility, or generalization.
Read more
Report

Growth

Hiring Momentum
53/100
Stable
Open positions
0
1 opened / 1 closed in 30 days
ATS activity
Every ~2 days
08/30/2026
Hiring Dynamics 0%